Our clinical trials main goal is to establish product safety and efficiency so that sales are done with the highest quality standards.
The collaboration with various Medical Institutions, Higher Education Institutions (HEI), Research Centers (RC), other companies, and the entire R & D team allows for a greater flow of information to get specific and effective results for decision making and product development.
Areas of interest:
•Hypertension
•Metabolic syndrome
•TB drugs
•Vitamins
•Pain treatment
•Antiparasitic
•Prevention of asthma and other related diseases
• Detection of HIV antibodies in serum or plasma with the HIV-Instantest test. • Detection of Trypanosoma cruzi antibodies to diagnose Chagas disease.
• Eye diseases
• Inflammatory diseases
• Neurodegenerative diseases
• Autoimmune disorders
• Infectious diseases
• Diabetes
National Toxicology Network (REDTOX)
Silanes Laboratories and the Bioclon Institute created the First National Network of Centers for Poisoning Control and Treatment (www.redtox.org) in order to advise the medical community on the treatments they must use to provide timely and suitable care for patients bitten by a poisonous animal.
Molecular biology laboratory
Silanes has a Molecular Biology laboratory, where techniques to develop recombinant proteins are implemented, giving service to the Antivenoms and Diagnostics departments in order to ensure enough antigen and antibody supply for product manufacturing.
The use of molecular biology has allowed us to prepare to face a new era at the globalized pharmaceutical industry: the use of biotechnological products such as drugs and customized medicine.
Molecular diagnosis
Through collaborative agreements with different public and private health agencies, Silanes ventures into genomics, mainly for gene ID among the Mexican population in order to predict the risk of diseases such as diabetes, hypertension and obesity.
Our goal is to participate in drug research, development and marketing tailormade for the Mexican population through pharmacogenomics. This will be possible as we learn more about the genetics of the different ethnic groups in the country.
Proteomics
In Silanes, hard work is being done towards an infrastructure that faces the challenges of future sciences such as the use of proteomics, by means of which disease markers with high diagnostic and therapeutic power will be described and characterized. With strategic partnerships, it will be possible to get involved, in the short term, in this post-genomic stage, in which the information obtained through the description of the human genome will now have to be translated into techniques and products that describe a body because of its genetic information. This will directly result in a better description of the diseases and their preventative diagnosis.